Variability in the CYP3A4 gene primarily affects the metabolism of abemaciclib, influencing its plasma levels, efficacy, and toxicity. Additionally, polymorphisms in the ABCG2 and ABCB1 genes, which encode efflux transporters, impact the transport and clearance of the drug, thereby affecting drug exposure and potential side effects.